Medicare Part D

2018 Top 20 Manufacturers by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
	Rank		Total Spending (US Dollars)			Total Claims
Manufacturer	2018	2017	2018	2017	Change	2018	2017	Change
Novo Nordisk	1	2	$8,222,356,732	$6,898,331,594	19.2%	12,314,485	11,411,055	7.9%
Gilead Sciences	2	1	$7,129,414,639	$7,728,362,544	-7.7%	2,601,572	2,621,806	-0.8%
GlaxoSmithKline	3	7	$7,089,401,127	$5,456,312,210	29.9%	24,951,624	19,267,295	29.5%
Janssen Pharmaceutica	4	9	$6,430,668,244	$5,165,868,234	24.5%	8,017,133	7,580,832	5.8%
Eli Lilly & Co.	5	8	$6,371,763,529	$5,221,521,369	22.0%	8,352,692	7,173,250	16.4%
Pfizer	6	6	$6,258,030,714	$5,471,985,434	14.4%	7,463,733	7,582,339	-1.6%
Boehringer Ingelheim	7	5	$6,036,676,227	$5,479,096,721	10.2%	9,667,651	10,087,470	-4.2%
Bristol-Myers Squibb (Primary Care)	8	13	$5,801,998,631	$4,071,217,902	42.5%	9,332,964	6,696,327	39.4%
Sanofi	9	4	$5,615,346,610	$5,876,896,802	-4.5%	8,634,163	10,171,339	-15.1%
Celgene	10	11	$5,385,466,322	$4,262,539,388	26.3%	441,216	389,037	13.4%
Abbvie	11	12	$5,199,631,477	$4,147,935,332	25.4%	7,270,010	7,463,794	-2.6%
Merck & Co.	12	3	$5,086,554,063	$5,919,364,129	-14.1%	7,702,509	10,201,168	-24.5%
AstraZeneca	13	10	$4,687,308,217	$4,396,063,246	6.6%	8,504,245	10,120,702	-16.0%
Allergan	14	15	$4,126,750,662	$3,348,164,587	23.3%	8,836,482	8,484,667	4.1%
Novartis	15	16	$3,715,402,380	$3,296,805,087	12.7%	1,540,606	1,303,629	18.2%
Amgen	16	14	$3,049,678,928	$3,810,316,288	-20.0%	1,186,010	1,771,230	-33.0%
Astellas Pharma	17	19	$2,947,053,280	$2,347,002,280	25.6%	3,756,629	3,590,609	4.6%
Mylan	18	17	$2,370,400,279	$3,007,196,638	-21.2%	80,489,940	109,426,340	-26.4%
Teva	19	18	$2,368,387,612	$2,643,467,557	-10.4%	84,822,623	99,774,558	-15.0%
Pharmacyclics	20	--	$1,867,207,013	$1,368,727,295	36.4%	165,236	131,205	25.9%
	Total US:		$168,138,935,017	$154,831,856,862	8.6%	1,500,933,893	1,495,932,077	0.3%

2017 Top 20 Manufacturers by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
	Rank		Total Spending (US Dollars)			Total Claims
Manufacturer	2017	2016	2017	2016	Change	2017	2016	Change
Gilead Sciences	1	1	$7,728,362,544	$9,150,351,018	-15.5%	2,621,806	2,585,780	1.4%
Novo Nordisk	2	4	$6,898,331,594	$5,829,000,577	18.3%	11,411,055	10,857,388	5.1%
Merck & Co.	3	3	$5,919,364,129	$6,309,495,770	-6.2%	10,201,168	13,251,487	-23.0%
Sanofi	4	5	$5,876,896,802	$5,497,556,841	6.9%	10,171,339	9,964,943	2.1%
Boehringer Ingelheim	5	6	$5,479,096,721	$4,884,636,249	12.2%	10,087,470	10,244,803	-1.5%
Pfizer	6	8	$5,471,985,434	$4,549,143,674	20.3%	7,582,339	9,067,115	-16.4%
GlaxoSmithKline	7	9	$5,456,312,210	$4,406,679,504	23.8%	19,267,295	15,777,603	22.1%
Eli Lilly & Co.	8	7	$5,221,521,369	$4,600,105,929	13.5%	7,173,250	7,415,887	-3.3%
Janssen Pharmaceutica	9	10	$5,165,868,234	$4,117,296,302	25.5%	7,580,832	6,712,656	12.9%
AstraZeneca	10	2	$4,396,063,246	$6,924,110,869	-36.5%	10,120,702	17,464,398	-42.0%
Celgene	11	12	$4,262,539,388	$3,366,124,400	26.6%	389,037	345,355	12.6%
Abbvie	12	11	$4,147,935,332	$3,487,944,174	18.9%	7,463,794	7,673,917	-2.7%
Bristol-Myers Squibb (Primary Care)	13	15	$4,071,217,902	$3,145,093,587	29.4%	6,696,327	4,865,494	37.6%
Amgen	14	13	$3,810,316,288	$3,262,399,419	16.8%	1,771,230	1,635,867	8.3%
Allergan	16	16	$3,296,805,087	$2,927,966,739	12.6%	1,303,629	1,265,068	3.0%
Novartis	16	18	$3,150,197,218	$2,597,571,270	21.3%	8,223,468	7,814,690	5.2%
Mylan	17	14	$3,007,196,638	$3,218,133,853	-6.6%	109,426,340	119,232,938	-8.2%
Teva	18	17	$2,643,467,557	$2,917,178,214	-9.4%	99,774,558	105,870,582	-5.8%
Astellas Pharma	19	20	$2,347,002,280	$2,138,837,999	9.7%	3,590,609	3,382,278	6.2%
Actavis	20	19	$2,251,001,423	$2,380,783,726	-5.5%	70,679,271	68,274,257	3.5%
	Total US:		$154,831,856,862	$145,433,264,419	6.5%	1,495,932,077	1,477,015,262	1.3%

2016 Top 20 Manufacturers by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
	Rank		Total Spending (US Dollars)			Total Claims
Manufacturer	2016	2015	2016	2015	Change	2016	2015	Change
Gilead Sciences	1	1	$9,150,351,018	$11,225,354,654	-18.5%	2,585,780	2,544,166	1.6%
AstraZeneca	2	2	$6,924,110,869	$7,753,664,144	-10.7%	17,464,398	21,805,467	-19.9%
Merck & Co.	3	3	$6,309,495,770	$5,678,688,281	11.1%	13,251,487	14,229,493	-6.9%
Novo Nordisk	4	4	$5,829,000,577	$5,255,638,480	10.9%	10,857,388	10,957,602	-0.9%
Sanofi	5	5	$5,497,556,841	$5,089,731,672	8.0%	9,964,943	9,662,707	3.1%
Boehringer Ingelheim	6	6	$4,884,636,249	$4,610,003,515	6.0%	10,244,803	10,871,844	-5.8%
Eli Lilly & Co.	7	9	$4,600,105,929	$3,417,674,428	34.6%	7,415,887	6,467,033	14.7%
Pfizer	8	12	$4,549,143,674	$3,341,437,095	36.1%	9,067,115	9,470,101	-4.3%
GlaxoSmithKline	9	7	$4,406,679,504	$3,817,792,711	15.4%	15,777,603	12,722,186	24.0%
Janssen Pharmaceutica	10	10	$4,117,296,302	$3,404,462,026	20.9%	6,712,656	6,009,261	11.7%
Abbvie	11	14	$3,487,944,174	$2,904,682,688	20.1%	7,673,917	8,030,312	-4.4%
Celgene	12	16	$3,366,124,400	$2,593,705,479	29.8%	345,355	280,329	23.2%
Amgen	13	15	$3,262,399,419	$2,708,334,121	20.5%	1,635,867	1,528,429	7.0%
Mylan	14	13	$3,218,133,853	$3,259,757,649	-1.3%	119,232,938	115,883,765	2.9%
Bristol-Myers Squibb (Primary Care)	15	--	$3,145,093,587	$1,828,586,395	72.0%	4,865,494	2,859,333	70.2%
Novartis	16	11	$2,927,966,739	$3,395,892,801	-13.8%	1,265,068	2,568,291	-50.7%
Teva	17	8	$2,917,178,214	$3,657,263,212	-20.2%	105,870,582	121,049,200	-12.5%
Allergan	18	20	$2,610,971,557	$2,034,472,714	28.3%	7,820,928	7,299,716	7.1%
Actavis	19	17	$2,380,783,726	$2,210,406,064	7.7%	68,274,257	68,204,078	0.1%
Astellas Pharma	20	--	$2,138,837,999	$1,748,071,054	22.4%	3,382,278	3,023,134	11.9%
	Total US:		$145,433,264,419	$135,512,673,016	7.3%	1,477,015,262	1,428,613,600	3.4%

2015 Top 20 Manufacturers by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
	Rank		Total Spending (US Dollars)			Total Claims
Manufacturer	2015	2014	2015	2014	Change	2015	2014	Change
Gilead Sciences	1	2	$11,225,354,654	$6,326,046,948	77.4%	2,544,166	2,279,044	11.6%
AstraZeneca	2	1	$7,753,664,144	$7,563,407,623	2.5%	21,805,467	23,486,666	-7.2%
Merck & Co.	3	3	$5,678,688,281	$5,044,214,608	12.6%	14,229,493	15,123,844	-5.9%
Novo Nordisk	4	8	$5,255,638,480	$3,490,034,209	50.6%	10,957,602	9,082,340	20.6%
Sanofi	5	4	$5,089,731,672	$4,243,225,226	19.9%	9,662,707	9,470,760	2.0%
Boehringer Ingelheim	6	5	$4,610,003,515	$4,124,320,757	11.8%	10,871,844	11,238,107	-3.3%
GlaxoSmithKline	7	6	$3,817,792,711	$3,881,837,403	-1.6%	12,722,186	13,960,682	-8.9%
Teva	8	10	$3,657,263,212	$3,455,959,593	5.8%	121,049,200	122,431,960	-1.1%
Eli Lilly & Co.	9	11	$3,417,674,428	$3,011,693,441	13.5%	6,467,033	7,180,820	-9.9%
Janssen Pharmaceutica	10	15	$3,404,462,026	$2,516,096,138	35.3%	6,009,261	4,787,040	25.5%
Novartis	11	7	$3,395,892,801	$3,863,083,293	-12.1%	2,568,291	7,188,143	-64.3%
Pfizer	12	9	$3,341,437,095	$3,480,269,683	-4.0%	9,470,101	12,386,894	-23.5%
Mylan	13	12	$3,259,757,649	$2,956,517,417	10.3%	115,883,765	105,231,757	10.1%
Abbvie	14	14	$2,904,682,688	$2,524,061,561	15.1%	8,030,312	8,706,684	-7.8%
Amgen	15	17	$2,708,334,121	$2,276,104,797	19.0%	1,528,429	1,410,060	8.4%
Celgene	16	20	$2,593,705,479	$2,035,838,371	27.4%	280,329	221,294	26.7%
Actavis	17	16	$2,210,406,064	$2,450,757,039	-9.8%	68,204,078	65,414,528	4.3%
Forest	18	19	$2,118,623,569	$2,188,375,522	-3.2%	8,274,359	9,644,100	-14.2%
Sandoz	19	18	$2,061,345,704	$2,210,984,888	-6.8%	87,818,507	84,169,013	4.3%
Allergan	20	--	$2,034,472,714	$1,621,838,552	25.4%	7,299,716	7,034,771	3.8%
	Total US:		$135,512,673,016	$117,720,692,334	15.1%	1,428,613,600	1,371,973,351	4.1%

2018 Top 20 Brands by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
		Rank		Total Spending (US Dollars)			Total Claims
Brand	Manufacturer	2018	2017	2018	2017	Change	2018	2017	Change
Eliquis	Bristol-Myers Squibb (Primary Care)	1	2	$4,992,184,164	$3,078,896,927	62.1%	9,091,996	6,352,159	43.1%
Revlimid	Celgene	2	1	$4,065,088,801	$3,312,773,264	22.7%	285,930	259,693	10.1%
Xarelto	Janssen Pharmaceutica	3	5	$3,358,810,708	$2,611,791,237	28.6%	5,896,570	5,246,070	12.4%
Januvia	Merck & Co.	4	3	$3,228,917,720	$2,786,062,255	15.9%	4,819,533	4,833,936	-0.3%
Lyrica	Pfizer	5	7	$2,950,257,661	$2,517,073,735	17.2%	5,222,362	5,072,269	3.0%
Advair	GlaxoSmithKline	6	8	$2,394,014,929	$2,374,829,262	0.8%	4,398,707	4,881,672	-9.9%
Humira	Abbvie	7	9	$2,388,794,497	$2,015,734,946	18.5%	394,616	370,804	6.4%
Lantus	Sanofi	8	4	$2,370,490,822	$2,632,361,498	-9.9%	4,475,777	5,236,023	-14.5%
Imbruvica	Pharmacyclics	9	18	$1,867,207,013	$1,368,727,295	36.4%	165,236	131,205	25.9%
Symbicort	AstraZeneca	10	13	$1,751,221,156	$1,510,965,216	15.9%	4,265,249	4,049,860	5.3%
Harvoni	Gilead Sciences	11	6	$1,726,263,039	$2,555,839,934	-32.5%	54,502	81,898	-33.5%
Novolog	Novo Nordisk	12	12	$1,712,623,585	$1,533,124,007	11.7%	2,353,586	2,187,255	7.6%
Levemir	Novo Nordisk	13	16	$1,584,105,950	$1,404,127,510	12.8%	2,645,315	2,491,598	6.2%
Ibrance	Pfizer	14	17	$1,507,730,890	$1,399,517,851	7.7%	131,229	125,619	4.5%
Spiriva	Boehringer Ingelheim	15	10	$1,425,533,899	$1,662,019,570	-14.2%	2,553,761	3,358,320	-24.0%
Trulicity	Eli Lilly & Co.	16	--	$1,360,642,452	$699,368,134	94.6%	1,383,713	813,053	70.2%
Victoza	Novo Nordisk	17	--	$1,341,681,068	$1,031,526,061	30.1%	1,112,950	951,281	17.0%
Lantus	Sanofi	18	11	$1,253,375,347	$1,554,220,868	-19.4%	2,445,913	3,259,639	-25.0%
Enbrel	Amgen	19	20	$1,247,769,463	$1,157,839,006	7.8%	218,062	224,688	-2.9%
Copaxone	Teva	20	14	$1,208,097,769	$1,499,560,947	-19.4%	185,180	231,985	-20.2%
		Total US:		$168,138,935,017	$154,831,856,862	8.6%	1,500,933,893	1,495,932,077	0.3%

2017 Top 20 Brands by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
		Rank		Total Spending (US Dollars)			Total Claims
Brand	Manufacturer	2017	2016	2017	2016	Change	2017	2016	Change
Revlimid	Celgene	1	2	$3,312,773,264	$2,661,602,600	24.5%	259,693	239,093	8.6%
Eliquis	Bristol-Myers Squibb (Primary Care)	2	9	$3,078,896,927	$1,926,316,212	59.8%	6,352,159	4,456,268	42.5%
Januvia	Merck & Co.	3	4	$2,786,062,255	$2,440,387,993	14.2%	4,833,936	4,743,204	1.9%
Lantus	Sanofi	4	3	$2,632,361,498	$2,526,426,478	4.2%	5,236,023	5,029,203	4.1%
Xarelto	Janssen Pharmaceutica	5	8	$2,611,791,237	$1,955,000,085	33.6%	5,246,070	4,403,891	19.1%
Harvoni	Gilead Sciences	6	1	$2,555,839,934	$4,399,701,570	-41.9%	81,898	141,708	-42.2%
Lyrica	Pfizer	7	7	$2,517,073,735	$2,099,262,044	19.9%	5,072,269	4,940,845	2.7%
Advair	GlaxoSmithKline	8	6	$2,374,829,262	$2,320,125,120	2.4%	4,881,672	5,195,116	-6.0%
Humira	Abbvie	9	12	$2,015,734,946	$1,638,715,583	23.0%	370,804	340,100	9.0%
Spiriva	Boehringer Ingelheim	10	10	$1,662,019,570	$1,819,084,754	-8.6%	3,358,320	4,153,691	-19.1%
Lantus	Sanofi	11	11	$1,554,220,868	$1,687,996,836	-7.9%	3,259,639	3,597,380	-9.4%
Novolog	Novo Nordisk	12	19	$1,533,124,007	$1,163,647,229	31.8%	2,187,255	1,886,285	16.0%
Symbicort	AstraZeneca	13	16	$1,510,965,216	$1,431,862,303	5.5%	4,049,860	4,142,775	-2.2%
Copaxone	Teva	14	15	$1,499,560,947	$1,434,106,075	4.6%	231,985	239,348	-3.1%
Sensipar	Amgen	15	18	$1,436,678,980	$1,225,973,011	17.2%	985,214	956,864	3.0%
Levemir	Novo Nordisk	16	17	$1,404,127,510	$1,419,146,165	-1.1%	2,491,598	2,545,577	-2.1%
Ibrance	Pfizer	17	--	$1,399,517,851	$995,095,215	40.6%	125,619	95,404	31.7%
Imbruvica	Pharmacyclics	18	--	$1,368,727,295	$978,350,728	39.9%	131,205	100,851	30.1%
Renvela	Genzyme	19	13	$1,316,266,396	$1,462,813,860	-10.0%	892,182	1,024,841	-12.9%
Enbrel	Amgen	20	--	$1,157,839,006	$999,159,620	15.9%	224,688	216,642	3.7%
		Total US:		$154,831,856,862	$145,433,264,419	6.5%	1,495,932,077	1,477,015,262	1.3%

2016 Top 20 Brands by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
		Rank		Total Spending (US Dollars)			Total Claims
Brand	Manufacturer	2016	2015	2016	2015	Change	2016	2015	Change
Harvoni	Gilead Sciences	1	1	$4,399,701,570	$7,030,633,486	-37.4%	141,708	225,792	-37.2%
Revlimid	Celgene	2	7	$2,661,602,600	$2,077,425,469	28.1%	239,093	204,870	16.7%
Lantus	Sanofi	3	3	$2,526,426,478	$2,483,335,172	1.7%	5,029,203	4,861,671	3.4%
Januvia	Merck & Co.	4	6	$2,440,387,993	$2,131,952,446	14.5%	4,743,204	4,623,600	2.6%
Crestor	AstraZeneca	5	2	$2,323,133,631	$2,883,122,484	-19.4%	6,013,547	8,712,212	-31.0%
Advair	GlaxoSmithKline	6	4	$2,320,125,120	$2,270,015,726	2.2%	5,195,116	5,649,301	-8.0%
Lyrica	Pfizer	7	10	$2,099,262,044	$1,766,473,720	18.8%	4,940,845	4,732,710	4.4%
Xarelto	Janssen Pharmaceutica	8	12	$1,955,000,085	$1,524,438,227	28.2%	4,403,891	3,831,489	14.9%
Eliquis	Bristol-Myers Squibb (Primary Care)	9	--	$1,926,316,212	$939,333,152	105.1%	4,456,268	2,400,991	85.6%
Spiriva	Boehringer Ingelheim	10	5	$1,819,084,754	$2,191,465,784	-17.0%	4,153,691	5,446,709	-23.7%
Lantus	Sanofi	11	9	$1,687,996,836	$1,876,168,995	-10.0%	3,597,380	3,993,659	-9.9%
Humira	Abbvie	12	19	$1,638,715,583	$1,211,645,971	35.2%	340,100	297,085	14.5%
Renvela	Genzyme	13	16	$1,462,813,860	$1,252,241,310	16.8%	1,024,841	997,644	2.7%
Zetia	Merck & Co.	14	18	$1,451,587,046	$1,227,881,419	18.2%	3,347,277	3,437,988	-2.6%
Copaxone	Teva	15	13	$1,434,106,075	$1,382,386,515	3.7%	239,348	237,976	0.6%
Symbicort	AstraZeneca	16	20	$1,431,862,303	$1,195,809,918	19.7%	4,142,775	3,693,933	12.2%
Levemir	Novo Nordisk	17	15	$1,419,146,165	$1,257,110,122	12.9%	2,545,577	2,328,543	9.3%
Sensipar	Amgen	18	--	$1,225,973,011	$945,234,754	29.7%	956,864	897,911	6.6%
Novolog	Novo Nordisk	19	--	$1,163,647,229	$1,089,595,668	6.8%	1,886,285	1,941,529	-2.8%
Nexium	AstraZeneca	20	8	$1,082,160,792	$2,012,920,920	-46.2%	3,006,677	5,471,140	-45.0%
		Total US:		$145,433,264,419	$135,512,673,016	7.3%	1,477,015,262	1,428,613,600	3.4%

2015 Top 20 Brands by Medicare Part D Drug Spending

Based on "Gross Drug Cost": Figures do not reflect any manufacturers’ rebates or other price concessions.

Data Source: U.S. Centers for Medicare & Medicaid Services.
		Rank		Total Spending (US Dollars)			Total Claims
Brand	Manufacturer	2015	2014	2015	2014	Change	2015	2014	Change
Harvoni	Gilead Sciences	1	--	$7,030,633,486	$699,892,572	904.5%	225,792	21,799	935.8%
Crestor	AstraZeneca	2	3	$2,883,122,484	$2,543,786,426	13.3%	2,019	2,018	0.0%
Lantus	Sanofi	3	7	$2,483,335,172	$2,016,972,757	23.1%	4,861,671	4,442,309	9.4%
Advair	GlaxoSmithKline	4	5	$2,270,015,726	$2,276,374,749	-0.3%	2,020	2,019	0.0%
Spiriva	Boehringer Ingelheim	5	6	$2,191,465,784	$2,158,439,227	1.5%	5,446,709	5,852,896	-6.9%
Januvia	Merck & Co.	6	8	$2,131,952,446	$1,775,295,533	20.1%	2,021	2,020	0.0%
Revlimid	Celgene	7	10	$2,077,425,469	$1,671,622,657	24.3%	204,870	178,377	14.9%
Nexium	AstraZeneca	8	2	$2,012,920,920	$2,660,421,777	-24.3%	2,022	2,021	0.0%
Lantus	Sanofi	9	9	$1,876,168,995	$1,725,595,629	8.7%	3,993,659	4,284,694	-6.8%
Lyrica	Pfizer	10	11	$1,766,473,720	$1,404,488,160	25.8%	2,023	2,022	0.0%
Abilify	Otsuka America	11	4	$1,572,428,343	$2,527,318,879	-37.8%	--	--	--
Xarelto	Janssen Pharmaceutica	12	14	$1,524,438,227	$1,090,914,810	39.7%	2,024	2,023	0.0%
Copaxone	Teva	13	13	$1,382,386,515	$1,221,108,238	13.2%	237,976	226,053	5.3%
Sovaldi	Gilead Sciences	14	1	$1,318,386,247	$3,106,960,981	-57.6%	2,025	2,024	0.0%
Levemir	Novo Nordisk	15	--	$1,257,110,122	$225,809,590	456.7%	2,328,543	441,136	427.9%
Renvela	Genzyme	16	--	$1,252,241,310	$865,864,598	44.6%	2,026	2,025	0.0%
Gleevec	Novartis	17	17	$1,232,939,891	$995,836,212	23.8%	125,076	118,319	5.7%
Zetia	Merck & Co.	18	16	$1,227,881,419	$1,035,066,332	18.6%	2,027	2,026	0.0%
Humira	Abbvie	19	--	$1,211,645,971	$871,312,974	39.1%	297,085	259,109	14.7%
Symbicort	AstraZeneca	20	19	$1,195,809,918	$942,361,512	26.9%	2,028	2,027	0.0%
		Total US:		$135,512,673,016	$117,720,692,334	15.1%	1,428,613,600	1,371,973,351	4.1%